65,437 trials
Adult Acute Lymphoblastic Leukemia in Remission
Primary: Disease Free Survival — 1.7 years
Type 2 Diabetes Mellitus
Primary: Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Week 4 — -37.9; -65.7; -38.1; -12.0 mg/dL — p=<0.001
Systemic Sclerosis · Scleroderma
Primary: Net Ulcer Burden — 1.0; 2.0; 0.0; -1.0 ulcers — p=0.20
Heart Failure · Asymptomatic Systolic Dysfunction
Primary: Change in Urinary Sodium Excretion in Response to Saline Load — 179.1; 3.1 mEq/min — p=<0.05
Trichotillomania
Primary: National Institute of Mental Health Trichotillomania Symptom Severity Scale — 7.94; 8.73 units on a scale
Hunter Syndrome · Mucopolysaccharidosis II (MPS II)
Primary: Change From Baseline in Mean Percent Predicted Forced Vital Capacity (FVC) at Week 105 — -0.056 percent predicted FVC
Type 1 Diabetes
Primary: Change in A1C From Baseline to End of Study Participation — 0.00; -0.04 Percent
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · Metastatic Osteosarcoma · Recurrent Adult Soft Tissue Sarcoma
Primary: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)
Pain
Primary: Classification of Pain During Labor by Visual Analogue Scale — 57.0; 72.1 mm — p=0.01
Epilepsies, Partial
Primary: Number of Treatment-Emergent Adverse Events (AEs) by Severity: Double-blind Treatment — 0; 2; 2; 4 adverse events
Breast Cancer
Primary: Clinical Response Rate — 47 Participants
Ischemic Stroke · Stroke · Brain Infarction
Primary: Symptomatic Intracranial Hemorrhage (sICH) Within 36 Hours of Treatment Onset — 3; 2; 22; 99 participants — p=0.053
Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of Celecoxib Combined With Radiation Therapy (RT) — 0; 1 units on a scale
Oxidative Stress
Primary: Intracellular Glutathione Level — 221.5; 118.5; 508.5; 358.0 µmol/L
Dupuytren's Contracture
Primary: Total Passive Extension Deficit (TPED) at Baseline for First Injection — 55.0 degrees